The antibody-drug conjugate market is on an exhilarating growth trajectory, fueled by innovative therapies and precision medicine. With advancements in targeted treatments and a surge in cancer cases, the demand for ADCs is skyrocketing. As biotech companies harness cutting-edge technology, the ADC market is poised to revolutionize cancer care and deliver hope to patients worldwide.
LAS VEGAS , Oct. 21, 2024 /PRNewswire/ -- DelveInsight's Antibody-drug Conjugate Market Insights report provides the current and forecast market analysis, individual leading antibody-drug conjugate companies' market shares, challenges, Antibody-drug Conjugate market drivers, barriers, trends, and key market antibody-drug conjugate companies in the market. Key Takeaways from the Antibody-drug Conjugate Market Report As per DelveInsight estimates, North America is anticipated to dominate the global antibody-drug conjugate market during the forecast period.
In the cancer type segment of the antibody-drug conjugate market, the breast cancer category is estimated to amass a significant revenue share in the antibody-drug conjugate market in 2023. Notable antibody-drug conjugate companies such as F. Hoffmann-La Roche Ltd, DAIICHI SANKYO COMPANY, LIMITED, Pfizer Inc.
, Gilead Sciences, Inc., ADC Therapeutics SA., GSK plc, Mersana Therapeutics.
, Astellas Pharma Inc., AstraZeneca, ImmunoGen Inc., and several others, are currently operating in the antibody-drug conjugate market.
In October 2024 , Avacta Group.